Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• William WN, Lin HY, Lee JJ, Lippman SM, Roth JA, Kim ES. Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest. 2009;136(3):701–709. doi:10.1378/chest.08-296819318668
   PubMed Web of Science ®Google Scholar
• Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012;343(2):342–350. doi:10.1124/jpet.112.19775622888144
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007;67(24):11924–11932. doi:10.1158/0008-5472.CAN-07-188518089823
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug Administration. FDA approves dacomitinib for metastatic non-small cell lung cancer. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dacomitinib-metastatic-non-small-cell-lung-cancer–0. Accessed 810, 2020.
   Google Scholar
• Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, Phase 3 trial. Lancet Oncol. 2017;18(11):1454–1466. doi:10.1016/S1470-2045(17)30608-328958502
   PubMed Web of Science ®Google Scholar
• Mok TS, Cheng Y, Zhou X, et al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018;36(22):2244–2250. doi:10.1200/JCO.2018.78.799429864379
   PubMed Web of Science ®Google Scholar
• Wang H, Naghavi M, Allen C, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–1544.27733281
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Nonsmall Cell Lung Cancer, Version 6. 2020.
   Google Scholar
• Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–640. doi:10.1056/NEJMoa161267427959700
   PubMed Web of Science ®Google Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103. doi:10.1001/jama.2016.1219527623463
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness–the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–797. doi:10.1056/NEJMp140515825162885
   PubMed Web of Science ®Google Scholar
• Wan X, Zhang Y, Tan C, Zeng X, Peng L. First-line nivolumab plus ipilimumab vs sunitinib for metastatic renal cell carcinoma: a cost-effectiveness analysis. JAMA Oncol. 2019;5(4):491–496. doi:10.1001/jamaoncol.2018.708630789633
   PubMed Web of Science ®Google Scholar
• Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011;11:139. doi:10.1186/1471-2288-11-13921985358
   PubMed Web of Science ®Google Scholar
• Ishak KJ, Kreif N, Benedict A, Muszbek N. Overview of parametric survival analysis for health-economic applications. Pharmacoeconomics. 2013;31(8):663–675. doi:10.1007/s40273-013-0064-323673905
   PubMed Web of Science ®Google Scholar
• Williams C, Lewsey JD, Mackay DF, Briggs AH. Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and markov decision-analytic modeling. Med Decis Making. 2017;37(4):427–439. doi:10.1177/0272989X1667061727698003
   PubMed Web of Science ®Google Scholar
• Diaby V, Adunlin G, Montero AJ. Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics. 2014;32(2):101–108. doi:10.1007/s40273-013-0123-924338265
   PubMed Web of Science ®Google Scholar
• Arias E. United States life tables, 2017. Natl Vital Stat Rep. 2019;68(7):1–66.
   PubMedGoogle Scholar
• Dansk V, Large S, Bertranou E, Bodnar C, Dyer M, Ryan JA. Review of health state utility values used in UK nice appraisals in advanced NSCLC. Value Health. 2016;19(7):A745–745A. doi:10.1016/j.jval.2016.09.2278
   Web of Science ®Google Scholar
• Nafees B, Lloyd AJ, Dewilde S, Rajan N, Lorenzo M. Health state utilities in non-small cell lung cancer: an international study. Asia Pac J Clin Oncol. 2017;13(5):e195–195,e203. doi:10.1111/ajco.1247726990789
   PubMed Web of Science ®Google Scholar
• Handorf EA, McElligott S, Vachani A, et al. Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung. J Oncol Pract. 2012;8(5):267–274. doi:10.1200/JOP.2011.00050223277762
   PubMedGoogle Scholar
• Klein R, Wielage R, Muehlenbein C, et al. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2010;5(8):1263–1272. doi:10.1097/JTO.0b013e3181e15d1620581708
   PubMed Web of Science ®Google Scholar
• Sands J, Li Q, Hornberger J. Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: an outcomes and total cost-of-care analysis. Lung Cancer. 2017;110:19–25. doi:10.1016/j.lungcan.2017.05.01428676213
   PubMed Web of Science ®Google Scholar
• The Drugs.com Database. Drug Price Information. Available from: https://www.drugs.com/price-guide/vizimpro.20200805. Accessed 520, 2021.
   Google Scholar
• Wan X, Luo X, Tan C, Zeng X, Zhang Y, Peng L. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: a United States-based cost-effectiveness analysis. Cancer. 2019;125(20):3526–3534. doi:10.1002/cncr.3236831287562
   PubMed Web of Science ®Google Scholar
• Kumar G, Woods B, Hess LM, et al. Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S. Lung Cancer. 2015;89(3):294–300. doi:10.1016/j.lungcan.2015.05.02026122345
   PubMed Web of Science ®Google Scholar
• Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group-6. Med Decis Making. 2012;32(5):722–732. doi:10.1177/0272989X1245834822990087
   PubMed Web of Science ®Google Scholar
• Aguiar PN, Haaland B, Park W, San Tan P, Del Giglio A, de Lima Lopes G. Cost-effectiveness of osimertinib in the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer. JAMA Oncol. 2018;4(8):1080–1084. doi:10.1001/jamaoncol.2018.139529852038
   PubMed Web of Science ®Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–125. doi:10.1056/NEJMoa171313729151359
   PubMed Web of Science ®Google Scholar
• Wu B, Gu X, Zhang Q, Xie F. Cost-effectiveness of osimertinib in treating newly diagnosed, advanced EGFR-mutation-positive non-small cell lung cancer. Oncologist. 2019;24(3):349–357. doi:10.1634/theoncologist.2018-015030257889
   PubMed Web of Science ®Google Scholar
• Ting J, Ho P T, Xiang P, Sugay A, Abdel-Sattar M, Wilson L. Cost-effectiveness and value of information of erlotinib, afatinib, and cisplatin-pemetrexed for first-line treatment of advanced EGFR mutation-positive non-small-cell lung cancer in the United States. Value Health. 2015;18(6):774–782. doi:10.1016/j.jval.2015.04.00826409604
   PubMed Web of Science ®Google Scholar